AVE 1231

Drug Profile

AVE 1231

Latest Information Update: 17 Mar 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sanofi-aventis
  • Class Antiarrhythmics
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atrial fibrillation

Most Recent Events

  • 05 Sep 2007 Data presented at the European Society of Cardiology Congress 2007 (ESC-2007) added to the Arrhythmias pharmacodynamics section
  • 07 Oct 2005 Phase-I clinical trials in Atrial fibrillation in Europe (unspecified route)
  • 19 Apr 2005 Preclinical trials in Atrial fibrillation in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top